A comparison of these meta-programs between paired samples from the same patients revealed that downregulation of NF-κB signaling (meta-program 2) was associated with tumor relapse following ASCT or R-chemotherapy, whereas the MYC-targeted program (meta-program 3) consistently showed a trend of downregulation after ASCT (Figure 2D). This evidence concerns the gene NFKB1 and neoplasm.